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The human parainfluenza viruses (HPIVs) are members of the Paramyxoviridae family of viruses and are a common cause of acute upper and lower respiratory infections. Although HPIV infections are generally mild and self-limiting, severe infections leading to hospitalization may occur, particularly in infants, young children, and immunocompromised individuals ([@B1]).

The HPIV virion encloses a single-stranded negative-sense RNA genome with a length of ∼15,000 nucleotides (nt), encoding the following 6 structural proteins: the nucleoprotein (NP), phosphoprotein (P), matrix protein (M), fusion protein (F), hemagglutinin-neuraminidase (HN), and large protein (L). HPIVs are subdivided into 2 genera, Respirovirus (Human respirovirus 1 \[HPIV-1\] andHuman respirovirus 3 \[HPIV-3\]) and Rubulavirus (Human rubulavirus 2 \[HPIV-2\] andHuman rubulavirus 4 \[HPIV-4\]). In the Netherlands, HPIVs were the third most common viral pathogen in noninfluenza respiratory infections (after rhinovirus and adenovirus) from 2006 to 2015, according to a National Institute for Public Health and the Environment (RIVM) report ([@B2]). Surprisingly, given the clinical frequency of HPIVs, as of 22 January 2019, there were no HPIV full genomes from the Netherlands identified in GenBank, leading to a knowledge gap in the local virus diversity. Also, given the importance of nucleic acid-based diagnostics, documenting local viral sequences is essential for maintaining sensitive clinical diagnostics capable of detecting locally circulating HPIV strains.

Eight samples from the years 2013 to 2016 that were positive for HPIV (HPIV-1, HPIV-2, HPIV-3, and HPIV-4) were randomly chosen ([Table 1](#tab1){ref-type="table"}). The HPIVs were isolated from respiratory patients (youngest, 2 months of age, and oldest, 63 years of age) and propagated in LLC-MK2 (ATCC CCL-7, *Macaca mulatta*, monkey, rhesus) cell lines. Passage 3 of each sample, except that of sample t146a305 (for which passage 2 was used), was subjected to real-time PCR ([@B3]) to confirm the presence of HPIV and then used as follows for direct sequencing. Total viral nucleic acid was extracted from the 8 culture supernatants using a High Pure viral RNA extraction kit (Roche, Mannheim, Germany) following the manufacturer's instructions. Extracted RNA was reverse transcribed using random hexamers that avoid rRNA ([@B4]), followed by second-strand synthesis using Klenow fragments (New England Biolabs), as previously described ([@B5]). The resulting double-stranded DNA (dsDNA) was used to prepare for sequencing libraries using an Ion Xpress Plus fragment library kit (part number 4471269) and subsequently sequenced on the Ion Torrent S5XL platform to generate 2.3 × 10^6^ to 5.1 × 10^6^ reads per sample (median read length, 275 to 300 nt). Raw reads were trimmed from the 3′ end to a median Phred score of 25 and minimum length of 75 nt using QUASR ([@B6]) and *de novo* assembled using SPAdes version 3.13.0 ([@B7]). In all samples, 1 to 2 contigs spanning the full genome were obtained; subgenomic contigs were combined using Geneious (version 9.1.8).

###### 

Clinical and sequence data for 8 HPIV samples

  Sample identifier   GenBank accession no.                                       SRR accession no.                                           BioSample no.                                                         Genome GC content (%)   Species                  HPIV genotype   Date of original sample (mo/day/yr)   Patient age   Clinical symptom(s)[^*c*^](#ngtab1.3){ref-type="table-fn"}                  Passage no. (LLC-MK2)   Cell culture *C~T~* value[^*d*^](#ngtab1.4){ref-type="table-fn"}   Genome length (nt)   No. of mapped reads[^*a*^](#ngtab1.1){ref-type="table-fn"}   Total no. of reads   Avg coverage (×)[^*b*^](#ngtab1.2){ref-type="table-fn"}
  ------------------- ----------------------------------------------------------- ----------------------------------------------------------- --------------------------------------------------------------------- ----------------------- ------------------------ --------------- ------------------------------------- ------------- --------------------------------------------------------------------------- ----------------------- ------------------------------------------------------------------ -------------------- ------------------------------------------------------------ -------------------- ---------------------------------------------------------
  t146a290            [MH892403](https://www.ncbi.nlm.nih.gov/nuccore/MH892403)   [SRR8512262](https://www.ncbi.nlm.nih.gov/sra/SRR8512262)   [SAMN10838957](https://www.ncbi.nlm.nih.gov/biosample/SAMN10838957)   37.2                    *Human respirovirus 1*   HPIV-1          10/28/2013                            9 mos         Respiratory insufficiency                                                   3                       16.7                                                               15,675               425,854                                                      1,927,124            6,792
  t146a291            [MH892404](https://www.ncbi.nlm.nih.gov/nuccore/MH892404)   [SRR8512263](https://www.ncbi.nlm.nih.gov/sra/SRR8512263)   [SAMN10838958](https://www.ncbi.nlm.nih.gov/biosample/SAMN10838958)   37.2                    *Human respirovirus 1*   HPIV-1          2/5/2013                              2 yrs         Pierre Robin syndrome, cleft, respiratory insufficiency, tracheal cannula   3                       19                                                                 15,422               17,598                                                       2,024,742            285
  t146a292            [MH892405](https://www.ncbi.nlm.nih.gov/nuccore/MH892405)   [SRR8512264](https://www.ncbi.nlm.nih.gov/sra/SRR8512264)   [SAMN10838959](https://www.ncbi.nlm.nih.gov/biosample/SAMN10838959)   38.4                    *Human rubulavirus 2*    HPIV-2          12/15/2014                            6 yrs         ILD, fever, and coughing                                                    3                       12.3                                                               15,684               18,263                                                       1,828,911            291
  t146a293            [MH892406](https://www.ncbi.nlm.nih.gov/nuccore/MH892406)   [SRR8512265](https://www.ncbi.nlm.nih.gov/sra/SRR8512265)   [SAMN10838960](https://www.ncbi.nlm.nih.gov/biosample/SAMN10838960)   38.7                    *Human rubulavirus 2*    HPIV-2          4/2/2014                              43 yrs        Increasing dyspnea, mucosal swelling, stridor, hoarseness                   3                       11                                                                 15,654               264,338                                                      1,939,223            4,222
  t146a304            [MH892409](https://www.ncbi.nlm.nih.gov/nuccore/MH892409)   [SRR8512258](https://www.ncbi.nlm.nih.gov/sra/SRR8512258)   [SAMN10838961](https://www.ncbi.nlm.nih.gov/biosample/SAMN10838961)   35.1                    *Human respirovirus 3*   HPIV-3          8/1/2016                              63 yrs        Respiratory insufficiency                                                   3                       10.6                                                               15,387               1,355,991                                                    4,099,107            22,031
  t146a305            [MH892410](https://www.ncbi.nlm.nih.gov/nuccore/MH892410)   [SRR8512259](https://www.ncbi.nlm.nih.gov/sra/SRR8512259)   [SAMN10838962](https://www.ncbi.nlm.nih.gov/biosample/SAMN10838962)   35.2                    *Human respirovirus 3*   HPIV-3          11/29/2013                            14 yrs        Fever, mucus                                                                2                       14                                                                 15,409               330,469                                                      2,589,260            5,362
  t146a296            [MH892407](https://www.ncbi.nlm.nih.gov/nuccore/MH892407)   [SRR8512260](https://www.ncbi.nlm.nih.gov/sra/SRR8512260)   [SAMN10838963](https://www.ncbi.nlm.nih.gov/biosample/SAMN10838963)   36.3                    *Human rubulavirus 4*    HPIV-4          11/8/2013                             2 mos         Respiratory insufficiency                                                   3                       11.5                                                               17,079               46,139                                                       1,743,284            675
  t146a303            [MH892408](https://www.ncbi.nlm.nih.gov/nuccore/MH892408)   [SRR8512261](https://www.ncbi.nlm.nih.gov/sra/SRR8512261)   [SAMN10838964](https://www.ncbi.nlm.nih.gov/biosample/SAMN10838964)   36.3                    *Human rubulavirus 4*    HPIV-4          9/13/2013                             8 mos         Tracheal cannula, URI                                                       3                       13.4                                                               17,031               21,081                                                       2,598,198            309

Total number of quality-controlled reads mapped to final genome.

Number of mapped reads times 250 divided by the length of the genome.

ILD, interstitial lung disease; URI, upper respiratory infection.

*C~T~*, threshold cycle.

Eight complete HPIV genomes were assembled from short-read data, and their open reading frames (ORFs) were checked to ensure intact ORFs. Results from BLAST searches of these genomes showed that they share 98% to 99% similarity at the nucleotide level with contemporary strains from Thailand (2012, GenBank accession number [KM190940](https://www.ncbi.nlm.nih.gov/nuccore/KM190940)) and France (2009, accession number [KF687313](https://www.ncbi.nlm.nih.gov/nuccore/KF687313)) for HPIV-1, from the United States (2016, accession number [KY674949](https://www.ncbi.nlm.nih.gov/nuccore/KY674949), and 2017, accession number [MF077312](https://www.ncbi.nlm.nih.gov/nuccore/MF077312)) for HPIV-2, from the United States (2015, accession number [KY973558](https://www.ncbi.nlm.nih.gov/nuccore/KY973558)) and France (2009, accession number [KF530233](https://www.ncbi.nlm.nih.gov/nuccore/KF530233)) for HPIV-3, and from Taiwan (2010, accession number [KY460518](https://www.ncbi.nlm.nih.gov/nuccore/KY460518)) for HPIV-4. Annotation for the open reading frames was performed in Geneious using information in the GenBank entries for the four reference genomes listed under the accession numbers [NC_003461](https://www.ncbi.nlm.nih.gov/nuccore/NC_003461) (HPIV-1), [NC_001796](https://www.ncbi.nlm.nih.gov/nuccore/NC_001796) (HPIV-3), [NC_003443](https://www.ncbi.nlm.nih.gov/nuccore/NC_003443) (HPIV-2), and [NC_021928](https://www.ncbi.nlm.nih.gov/nuccore/NC_021928) (HPIV-4).

In conclusion, we report here the first 8 genomes of HPIV isolated from the Netherlands.

Data availability. {#s1.1}
------------------

The eight HPIV genomic sequences described in this study have been deposited in GenBank under the accession numbers [MH892403](https://www.ncbi.nlm.nih.gov/nuccore/MH892403) to [MH892410](https://www.ncbi.nlm.nih.gov/nuccore/MH892410), with the BioSample and run accession numbers shown in [Table 1](#tab1){ref-type="table"}. The corresponding short-read data are available in the SRA under the BioProject accession number [PRJNA517593](https://www.ncbi.nlm.nih.gov/bioproject/PRJNA517593).
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